Noopur Raje, MD

In this engaging discussion, Prof. Philippe Moreau from France, Dr. Robert Z Orlowski from MD Anderson, Dr. Noopur Raje from Massachusetts General, and Dr. Paul G Richardson delve into the complexities of managing multiple myeloma. They tackle innovative treatment strategies, including the use of CD38 antibodies, novel therapies, and the importance of minimal residual disease as a prognostic marker. The conversation also covers challenges in treating elderly patients, the role of CAR T-cell therapies, and the potential of the new BELLA drug in improving outcomes.

Experts discuss recent updates in CAR-T and cellular therapy, including T cell engineering, CRISPR gene disruption, mesenchymal stem cells for COVID-19 pneumonia, and CAR-T cell therapy in challenging patient populations. They also analyze studies on CAR-T cell therapy, comparing management of toxicities, eligibility criteria, and durable responses. Additionally, they explore a comparison study between exocaptogen, CIBMTR, and T-stinlucil, and the potential of gene-edited effector cell therapy.